Ignite Creation Date:
2024-05-06 @ 2:22 AM
Last Modification Date:
2024-10-26 @ 11:17 AM
Study NCT ID:
NCT02023359
Status:
COMPLETED
Last Update Posted:
2015-12-29
First Post:
2013-12-23
Brief Title:
Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor HR Positive Human Epidermal Growth Factor 2 HER2 - Metastatic Breast Cancer
Sponsor:
Organization:
Novartis
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
False
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
7
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
| Name |
|---|
| Cohort |
Time Perspective List:
Clinical Trial Statuses
| Name |
|---|
| 24028 |
Who Masked List: